A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
about
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationProphylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantationPathogen-reduced platelets for the prevention of bleedingPathogen inactivation technologies for cellular blood components: an updateMeta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system.Inverse probability weighted estimating equations for randomized trials in transfusion medicine.Pathogen reduction technologies: The pros and cons for platelet transfusion.Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Component pathogen inactivation: a critical review.Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for TransfusionA patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States.The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.Update on the use of pathogen-reduced human plasma and platelet concentrates.Pathogen-reduced platelets for the prevention of bleeding.Will pathogen reduction of blood components harm more people than it helps in developed countries?Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations.Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.Inhibiting GPIbα Shedding Preserves Post-Transfusion Recovery and Hemostatic Function of Platelets After Prolonged Storage.Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearanceReducing the financial impact of pathogen inactivation technology for platelet components: our experience.Evaluation of amotosalem treated platelets over 7 days of storage with an automated cytometry assay panel.Costs and benefits of PAS platelets: a mix of science, quality, and value.Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets.In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.Coagulation profile after plasma exchange using albumin as a replacement solution measured by thromboelastometry.Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.Routine use of Day 6 and Day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation.Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.Response to "An unbalanced study that lacks power: a caution about IPTAS".Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.Bacterial contamination of platelets for transfusion: strategies for preventionBudget impact of implementing platelet pathogen reduction into the Italian blood transfusion system
P2860
Q24186359-64588C0A-D0EE-4120-9DEB-7869F110E08CQ24186913-F698A633-7C6E-4B31-9D74-BAE693C8CA23Q24187751-29B43BA9-DC79-4A69-8B49-38D06B3172FEQ24197779-E807E672-E8EB-4132-BF15-E14808DE5EB5Q24199041-FBCA1CF5-9A26-411E-BB54-EBE3220C11CDQ28655769-245CAEBB-5EE8-4FEB-9520-70E094A7A25FQ33397396-25EEB86E-2040-4C09-8880-57A9A2876383Q33407359-E8FEF731-3ADE-4278-BBFA-5CDAC2138BF3Q33441980-8C728FF9-3634-4810-A36A-A85480443A42Q33841435-9E495E70-F8DA-46F8-9E4F-AE48D6E504B1Q34310415-16D75678-F406-4EA9-AF90-F84603C16B78Q36283203-A9643488-9733-4C94-935D-DFFBB05B916DQ38052141-F238E63E-CD9A-4B2B-824F-AB0A11150F3AQ38073018-19F27922-CCDA-4283-83C0-C6D6749E449EQ38109665-A449EE77-32C0-40A3-89EA-06757A3C1506Q38653240-E3E0D9F9-DF38-4B81-8C42-3F153435B818Q38831832-926B81F3-F4E9-4E6A-BAC0-56B6C4E3A8B1Q39521376-F81B9E1B-D89A-4613-918C-CFCA1BFC3BC3Q40318288-B38B1239-FD4F-4843-984A-B1C15FFB16CDQ40335808-1FBCDFC1-6784-4270-B7B6-2FE1F3C55DEDQ40413938-7128850B-C30C-4C13-8A92-A923BDC97754Q40958985-A823A570-23C8-4A93-A044-90A6AAE849D8Q42368316-E370B1B7-599D-4A9D-99F8-9B5308C87D06Q44023975-03D0AFCC-FCC6-421C-9A6C-31FBC25F6FF0Q44412209-57830544-D53D-4E07-B326-2200EDD79EE9Q44553130-65279AEC-6E92-456C-A977-E051FC2E194DQ44827919-DB289B21-3A1C-4E89-801E-193A2D1CE9A7Q45966928-6A486F21-FAEB-4118-9547-37932B25E2EBQ46743693-E6FBE806-4539-4483-8903-11AE71D75B25Q47651286-4C8F9B91-25C7-4512-ACC0-36A6FD285B1CQ47799625-FDF17460-E5D8-4072-9BB3-E04648ACE56EQ50052949-1A921E51-65EE-411C-B1B7-E6FAE9AA4AFFQ50215380-FC876E39-CC4B-4DA7-9418-E3DE33F7164EQ50227054-81852EFB-8048-4623-936D-F56CE860F907Q50499990-8D1B1FEA-B1E6-416B-9D66-9F431A9FB21EQ58110468-30CD2D0F-3649-469A-B7FC-69D394EBACAFQ58701334-BAD39310-5AD7-4A7C-80F7-63A7FC8443F6
P2860
A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A multi-centre study of therap ...... 6 or 7 d prior to transfusion.
@en
A multi-centre study of therap ...... 6 or 7 d prior to transfusion.
@nl
type
label
A multi-centre study of therap ...... 6 or 7 d prior to transfusion.
@en
A multi-centre study of therap ...... 6 or 7 d prior to transfusion.
@nl
prefLabel
A multi-centre study of therap ...... 6 or 7 d prior to transfusion.
@en
A multi-centre study of therap ...... 6 or 7 d prior to transfusion.
@nl
P2093
P2860
P1476
A multi-centre study of therap ...... 6 or 7 d prior to transfusion.
@en
P2093
Anthony Docherty
Chris Prowse
Claire Sherman
Folke Knutson
Helena Löf
Huw Roddie
Jane Pelly
Laurence Corash
Meisa Propst
P2860
P304
P356
10.1111/J.1365-2141.2011.08635.X
P407
P577
2011-03-21T00:00:00Z